Horseshoe Crabs Rejoice: US Pharmacopeia Allows Companies To Stop Using These Living Beings In Their Toxicity Tests, Favoring Non-Animal Derived Testing Procedures

Share

Historic Policy Change: Pharma Now Has Green Light to Save Horseshoe Crabs

Editor’s note: We’ve previously covered the knowledge of animals and their ability to treat themselves with herbs and plants.

The following is from the statement made by the Horseshoe Crab Recovery Coalition, published on the site of the Humane Society of the United States:

The Horseshoe Crab Recovery Coalition, a coalition of more than 50 conservation and healthcare organizations including the Humane Society of the United States, applauds the U.S. Pharmacopeia’s Microbiology Expert Committee for voting to adopt Chapter 86: Bacterial Endotoxins Test Using Recombinant Reagents. This new chapter creates a standard for the biomedical industry’s use of a synthetic alternative to horseshoe crab blood in bacterial endotoxin testing.

Horseshoe crabs are facing mounting pressures across the Atlantic Coast. One of those pressures is the biomedical harvest of horseshoe crabs for their blue blood, which is used to create the Limulus amebocyte lysate test. Medical devices and injectable drugs are all tested for contaminants—or endotoxins—to ensure safety. Currently, most pharmaceutical companies use LAL. This comes at a high cost to horseshoe crabs and coastwide conservation.

“Shorebirds including the federally threatened Red Knot rely on horseshoe crab eggs during their migratory journeys that span thousands of miles each year. Widespread adoption of synthetic alternatives by the biomedical industry can alleviate harvest pressures and conserve horseshoe crabs,” said Annie Chester, policy director at the American Bird Conservancy. “This has the dual benefit of advancing bird conservation and human health.”

“We are delighted that USP has provided guidance that will help place recombinant testing on equal footing with LAL,” added Larry Niles, co-founder of HCRC. “Recombinant testing provides a reliable, sustainable alternative that is critical to horseshoe crab conservation and a healthy ecosystem throughout the Atlantic coast.”

[On November 1st, 2024], policy change goes into effect that allows companies to stop using horseshoe crab blood in the safety testing of new products.

The United States Pharmacopeia, a quality standards group that indicates which tests are accepted in manufacturing, has published for early adoption a policy that now allows the use of non-animal derived tests. This change will benefit and protect wildlife as well as improve accuracy within the pharmaceutical testing process.

Horseshoe crabs are remarkable animals that have lived on Earth since the time of the dinosaurs. They have survived so much – mass extinctions, asteroid impacts, and numerous other threats to their existence. Through the millennia, they have come to belong to a diverse coastal ecosystem that includes shorebirds, fish, sea turtles, sharks, raccoons, and foxes. In recent decades, horseshoe crabs have faced a new threat; they are caught in the wild, restrained, and bled through a needle to the heart. This is because horseshoe crab blood is used in some versions of a very important safety test.

During product manufacturing, makers of injectable drugs, vaccines, and implanted medical devices must test every batch of the product to ensure they are free of contaminants called endotoxin. Endotoxins can cause toxic effects like fever, septic shock, and inflammation. An enzyme found in the blue blood of horseshoe crabs clots in the presence of endotoxin. Fortunately, multiple testing options are now commercialized that allow companies to skip the blood-based tests, instead opting for the horseshoe crab-free versions that tout a well-rounded suite of advantages.

  • Scientific: Blood-based endotoxin tests are known to indicate false positives, meaning that with frequency they incorrectly indicate the presence of contaminants when contaminants are not present. As a synthetic product, the horseshoe crab-free tests do not contain the enzyme that triggers false positives. Why not avoid this issue altogether by going horseshoe crab-free?
  • Supply Chain: Horseshoe crab-free methods help avoid supply chain vulnerabilities associated with depending on the blood of wild animals that are subject to environmental pressures, instead offering a stable, scalable supply chain not subject to environmental pressures. Many of the remaining horseshoe crabs in the United States are located in the Delaware Bay. What happens in case of an oil spill?
  • Economic: Given the high cost of medical products, companies must do all they can to keep the cost of research and development down. In the case of a supply chain disruption, it is reasonable to expect price hikes. Why not adopt the synthetic versions as a protective hedge against potential price hikes?
  • Environmental: Horseshoe crabs are in trouble, negatively impacting the individual animals, the species, and other animals as well. Declining and unwell horseshoe crabs have already impacted shorebirds that depend on the eggs of the horseshoe crab for sustenance on their migratory paths. For example, the red knot, which makes its way to the Delaware Bay from South America and relies on horseshoe crab eggs to fuel their long migration, is now threatened. Adopting horseshoe crab-free methods allow companies to meet sustainability and environmental goals.
  • Animal Protection: To obtain the blood of horseshoe crabs, the animals are taken from the coast and transported to bleeding facilities, where as much as 1/3 of their blood is drained. The research and testing community has widely accepted the principle of replacement of animal testing where possible, meaning that non-animal methods be used where available and applicable. The many available synthetic versions allow companies to safely test for endotoxin while reducing and replacing animals, which helps companies carryout goals around reduction and replacement of animal testing.

Despite these benefits, until today, policy has made it difficult for companies to make the switch. In pharma, Eli Lilly has crusaded this cause. As early adopters of the horseshoe crab-free tech, Lily has already transitioned 80% of its testing to the horseshoe crab-free options and is working to close out use of horseshoe crab blood completely. Multiple other companies are moving in the direction of horseshoe crab-free methods, having transitioned varying amounts of their testing, but many have been awaiting this policy change to support making the switch.

Indeed, the business case for making the switch and sparing horseshoe crabs has never been stronger. When science progresses, we can do better, helping people and protecting animals. Let’s celebrate this win for horseshoe crabs and for humans!

Banner Image: Horseshoe crabs. Image Credit – Goodfreephotos_com


Share

Physicians Committee for Responsible Medicine

The Physicians Committee combines the clout and expertise of more than 17,000 physicians with the dedicated actions of nearly one million members and supporters worldwide. The Physicians Committee is a 501(c)(3) nonprofit organization, headquartered in Washington, DC. Our efforts are dramatically changing the way doctors treat chronic diseases such as diabetes, heart disease, obesity, and cancer. By putting prevention over pills, doctors are empowering their patients to take control of their own health. And we are also building a new way of viewing research. Since 1985, the Physicians Committee has worked tirelessly for alternatives to the use of animals in medical education and research and for more effective scientific methods. Our staff of physicians, dietitians, and scientists is working with policymakers, industry, the medical community, the media, and the public to create a better future for people and animals.

There are no comments yet

Why not be the first

Leave a Reply

Your email address will not be published. Required fields are marked *

*

code